| Ytd | -3.30% | |
| 1y | 59.68% |
| Open | 15.52 | Prev Close | 15.46 | Low | 14.92 | High | 15.52 | Mkt Cap | 527.09M |
| Vol | 30.15K | Avg Vol | 183.94K | EPS | -0.58 | P/E | -26.66 | Forward P/E | -10.90 |
| Beta | 1.88 | Short Ratio | 2.85 | Inst. Own | 82.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 16.20 | 200-d Avg | 14.95 | 1yr Est | 16.17 |
NPCE News
NPCE's RNS adoption, referral growth and AI innovation support expansion, while IGE timing and inves
The mean of analysts' price targets for NeuroPace (NPCE) points to a 27.9% upside in the stock. Whil
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?
NPCE rides strong RNS adoption and AI tools nearing FDA review, with a mid-2026 IGE decision offerin
NeuroPace wins FDA OK for ECoG Assistant, its first AI feature for epilepsy care, leveraging RNS EEG
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc
NeuroPace exits DIXI, doubles down on RNS as Q1 narrows losses and lifts 2026 guidance, Medicare and
NeuroPace tightens focus on its RNS epilepsy implant, exits DIXI distribution and pushes AI + cloud
NPCE bets on AI ECoG Assistant and cloud upgrades as it refocuses on RNS, while IGE label review and
NeuroPace raises revenue guidance for 2026 after Q1 sales beat estimates and losses narrow, driven b
NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call Transcript
NeuroPace NASDAQ: NPCE raised its 2026 revenue outlook after reporting first-quarter results that ma
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc
NeuroPace (NPCE) was a big mover last session on higher-than-average trading volume. The latest tren
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc
NeuroPace (NASDAQ: NPCE - Get Free Report) and Advanced Biomedical Technologies (OTCMKTS:ABMT - Get
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc
Integer (NYSE: ITGR - Get Free Report) and NeuroPace (NASDAQ: NPCE - Get Free Report) are both medic
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn
On Tuesday, 120 companies set new 52-week lows.
On Tuesday, 838 companies hit new 52-week lows.
On Wednesday, 329 companies hit new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
Tuesday's session saw 211 companies set new 52-week lows.
On Monday, 71 stocks hit new 52-week lows.
On Friday, 209 companies set new 52-week lows.
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report